Modeling the effects of resection, radiation and chemotherapy in glioblastoma

Journal of Neuro-Oncology

Volumn 91, Issue 3, 2009, Pages 287-293

  Tian, Jianjun Paul ^a   Friedman, Avner ^b   Wang, Jin ^c   Chiocca, E Antonio ^b  

^a The College of William and Mary   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OLD DOMINION UNIVERSITY   (United States)

Author keywords

Chemotherapy; Glioblastoma; Mathematical modeling; Radiation; Resection

Indexed keywords

ANTINEOPLASTIC AGENT; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; NEUROSURGICAL PROCEDURES; RADIOTHERAPY; TIME FACTORS;

EID: 58149461120     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9710-6     Document Type: Article

References (14)

1. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45-61
2. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al (2001) A multivariate analysis of 416 patients with glioblastoma mltiforme: Prognosis, extent of resection, and survival. J Neurosurg. 95:190-198
3. Stupp S, Mason WP, Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
4. Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J (2006) Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity. Cancer Res 66:2314-2319
5. O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902-1909
6. Rew DA, Wilso GD (2000) Cell production rate in human tissues and tumours and their significance. Part II: Clinical data. Eur J Surg Oncol 26:405-417
7. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al (2006) Cyclophospharnide enhances glioma virotherapy by inhibiting innate immune responses. Pro Nat Acad Sci 103:12873-12878
8. Fowler JF (1991) The phantom of tumor treatment - continually rapid proliferation unmasked. Radiother Oncol 22:156-158
9. Stummer W, Reuler HJ, Meinel T et al (2008) Extend of resection and survival in glioblastoma multiforme: Identification and adjustment for bias, Neurosurgery 62:1-11
10. Werner-Wasik M, Scott CB, Nelson DF et al (1996) Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02. Cancer 77:1535-1543
11. Chang EL, Yi W, Allen PK, et al (2003) Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: Outcome and prognostic factors, Int J Radiat Oncol Biol Phys 56:519-528
12. Sultanem K, Patrocinio H, Lambert C et al (2004) The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: Preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58:247-252
13. Floyd NS, Woo SY, Teh BS (2004) Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol 58:721-726
14. Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomogram for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981/CE.3. http://Oncology.Lancet.com, 9:29-38